These constraints restrict our ability to verify our findings, assess temporal dynamics and the origin of these autoantibodies, and explore potential causal relationships, including reverse causality, such as the presence of tau antibodies in patient cohorts with renal diseases. The gene discussed is MAPT; the disease is kidney disorder.